

# The Emergence of Hypervirulent M1T1 Clone of Group A *Streptococcus* via Genetic Recombination and Host Selection

Guanghai Liu<sup>1\*</sup>

<sup>1</sup>Division of Medical Protein Chemistry, Lund University, 21428 Malmö, Sweden

\*Corresponding email: [ghliu83@gmail.com](mailto:ghliu83@gmail.com)

## Abstract

*Streptococcus pyogenes* (Group A *Streptococcus*, GAS) is a strictly human bacterial pathogen. Since the mid-1980s, GAS M1T1 clone has been the most prevalent and globally disseminated serotype and is the culprit causing invasive and severe streptococcal infections, urging a better understanding of the emergence of hypervirulent M1T1 clone from an evolutionary perspective. This review highlights the molecular and evolutionary events leading to pandemic M1T1 strains, and discusses the pressure driving the genetic acquisition of novel virulence genes and the selection of hypervirulent isolates in host. By understanding the evolutionary selection and pressures that select and shape the pandemic M1T1 clone, we could potentially develop new therapeutic strategies to tackle challenges when dealing with the globally disseminated M1T1 GAS clone.

## Introduction

*Streptococcus pyogenes* is a Gram-positive human-restricted pathogen causing  $\beta$ -hemolysis of red blood cells and also known as Group A *Streptococcus* (GAS) due to the Lancefield group A antigen expressed on its surface (Lancefield, 1933). GAS primarily colonizes the nasopharynx and the skin of healthy people including children, without causing symptoms of diseases (Kline and Runge, 1994; Shaikh et al., 2010). However, when epithelial barrier damage occurs or our immunity becomes weakened, GAS is able to pass through the nasopharynx or skin barrier, and causes a wide variety of infections in human (Carapetis et al., 2005; Ralph and Carapetis, 2013). These infections result in mild diseases such as pharyngitis (strep throat) and impetigo (skin infection), and severe and life-threatening diseases such as necrotizing fasciitis (the flesh-eating disease) and streptococcal toxic shock syndrome (Carapetis et al., 2005; Ralph and Carapetis, 2013). Moreover, people infected by GAS have a risk to develop autoimmune complications, e.g., rheumatic fever and acute postinfectious glomerulonephritis (Carapetis et al., 2005; Ralph and Carapetis, 2013). It is estimated that 700 million GAS infections occur worldwide each year, of which 2.9% of cases are severe and invasive, leading to more than 500,000 deaths per year (Carapetis et al., 2005).

In concert with its strikingly capacity to cause diseases, GAS has been well equipped to colonize various hostile niches and to evade host protective immunity (Cole et al., 2011; Lappin and Ferguson, 2009; Olsen and Musser, 2010). In addition to the nasopharynx and the skin, GAS has been identified as an infectious agent in muscle, kidney, lung, heart, and brain (Cole et al., 2011; Lappin and Ferguson, 2009; Olsen and Musser, 2010). To colonize and invade these tissues and organs, GAS needs to overcome tissue barriers and the immune defense elicited in various niches. To cause necrotizing fasciitis, GAS exhibits sophisticated virulence mechanisms that initiate host cell adhesion, soft tissue entry, immune evasion and tissue destruction (Olsen and Musser, 2010). In patients with streptococcal toxic shock syndrome, GAS releases superantigens to bypass normal antigen processing, causing a cytokine storm that induces an acute multi-organ failure (Lappin and Ferguson, 2009).

The most known virulence factor of GAS is the M protein, which interacts with its host ligands, *e.g.*, complement, immunoglobulins and fibrinogen, playing relevant immunomodulatory functions (Smeesters et al., 2010). As a highly variable molecule, M protein together with surface T antigen are employed to classify GAS serotypes (Lancefield, 1962). Among the >200 GAS known serotypes, M1 is the most frequently identified serotype associated with severe and invasive infections (Steer et al., 2009; Sumby et al., 2005b). For example, M1 isolates share 18.3% of all GAS isolates worldwide, and particularly dominate in high-income countries, Asia, and Latin America (Steer et al., 2009). However, since the mid-1980s, the subclone of M1 GAS, M1T1, has been rising to be the most prevalent and globally disseminated serotype and deserved greater attention (Aziz and Kotb, 2008; Maamary et al., 2012; Nasser et al., 2014; Sumby et al., 2005b).

In recent years, omics studies have provided more evolutionary and molecular based evidence for the success of M1T1 clone. This clone evolves through a series of genetic recombination events that acquire genetic regions encoding significant streptococcal virulence factors (Aziz and Kotb, 2008; Nasser et al., 2014; Steer et al., 2009; Sumby et al., 2005b). Furthermore, the M1T1 clone frequently undergoes spontaneous mutations in its major regulatory genes, leading to the emergence of hypervirulent isolates with distinctive switching of phenotypes (Aziz et al., 2004b; Ikebe et al., 2010). This review aims to outline the molecular and evolutionary events leading to pandemic M1T1 strains, and to pinpoint the mechanisms governing the phenotypic shift of M1T1 GAS clone, which underlie the selection of hypervirulent isolates in the host.

## **I. Genetic acquisition of novel virulence genes determines the success of M1T1 GAS clone**

The past 30 years have witnessed the emergence of the highly successful M1T1 GAS clone. Comparing to other non-M1 and noninvasive M1 types of GAS, M1T1 clone shows more advantages in host adaptation, survival, persistence and dissemination (Maamary et al., 2012; Nasser et al., 2014). These M1T1 clones

including widely studied MGAS2221 and strain 5448, are more virulent in mouse and primate model of pharyngitis and invasive infections (Aziz et al., 2005; Sumby et al., 2005b). How M1T1 clone developed such advantages remained a mystery until high-throughput sequencing technologies were adopted to comparatively analyze genetic compositions of pandemic M1T1 clonal isolates. The comparative genetic analysis reveals that the emergence of M1T1 clone is attributed to two genetic recombination events that acquire regions encoding significant streptococcal virulence factors (Aziz and Kotb, 2008; Maamary et al., 2012; Nasser et al., 2014; Sumby et al., 2005b). The acquisition of these genes in a stepwise fashion confer the versatile capacity of M1T1 GAS in host adaptation and invasiveness through synergistic effects.

### *1. The first event: acquisition of bacteriophage-encoded DNase Sda1 and superantigen SpeA2*

Genomic analysis demonstrates the presence of novel bacteriophages or prophages encoding the extracellular deoxyribonuclease (Sda1, also called SdaD2) and the streptococcal pyrogenic exotoxin A (SpeA2) in the genome of M1T1 clones (Aziz et al., 2005; Banks et al., 2004). Although GAS harbors remarkable bacteriophages, which account for more than 10% of the total genome in certain M serotypes (Beres et al., 2002; Ferretti et al., 2001), the novel bacteriophages encoding DNase Sda1 and superantigen SpeA2 are exclusively found in the invasive strains, particularly in the epidemic M1T1 clone. Early at 1996, Cleary et al. observed that the pandemic M1T1 subclone differs from its closely related M1 subtypes by nearly 70 kb of two prophage DNA (Cleary et al., 1998). Through analysis of a M1T1 genome, Aziz et al. reported that these unique prophages encoding Sda1 and SpeA2 were introduced horizontally into the M1T1 global strain, and proposed that such a genetic recombination could contribute to the emergence and diversification of the M1T1 subclone (Aziz et al., 2005; Aziz and Kotb, 2008). The precise genetic recombination was later elucidated by Maamary and colleagues (Maamary et al., 2012). They showed that the acquisition of Sda1 occurred relatively early in the molecular evolutionary history of M1T1 strains, followed by acquisition of the superantigen SpeA2 (Maamary et

al., 2012; Nasser et al., 2014). Notably, the acquisition of Sda1 and SpeA2 does not necessarily improve the ability of M1 GAS to survive the killing of human neutrophils *in vitro* (Maamary et al., 2012). Instead, Sda1 and SpeA2 increase GAS virulence in the subcutaneous infection model of humanized plasminogen transgenic *AlbPLG1* mice (Maamary et al., 2012). However, M1 strain SF370, which contains four different bacteriophages encoding several superantigen-like proteins but not Sda1 and SpeA2, is less virulent and noninvasive, and genetically viewed as a pre-epidemic M1 serotype (Ferretti et al., 2001). To some extent, the acquisition of Sda1 and SpeA2 can be defined as evolutionary markers that distinguish epidemic M1T1 from non-invasive M1T1 and M1 serotypes.

### 1.1 DNase Sda1 and its role in GAS virulence

M1T1 GAS clone secretes several distinct DNases. Of these DNases, Sda1, was originally discovered by Aziz et al. in 2004 in culture supernatant of a M1T1 clinical isolate. Sda1 was determined to be bacteriophage-encoded (Aziz et al., 2004a) and found to be highly similar in amino-acid composition to streptodornase D from M49 GAS. Recombinant Sda1 can degrade both streptococcal and mammalian DNA, and its nuclease activity depends on the availability of divalent metal ions such as Ca<sup>++</sup> and Mg<sup>++</sup> (Aziz et al., 2004a). The crystal structure of Sda1 has been recently solved, revealing surface residues of Sda1 such as Arg12 and Asn211 involved in DNA binding and catalysis (Moon et al., 2016). It has been shown that Sda1 expression is regulated by the peroxide responsive regulator PerR under oxidative stress (Wang et al., 2013). However, the cysteine proteinase SpeB secreted by GAS seems to play a key role in controlling Sda1 expression by degrading Sda1 (Nelson et al., 2011; Walker et al., 2007).

Sda1 is a virulence factor of GAS with multi-faceted functions. Sumbly et al. demonstrated that Sda1 alone is sufficient to induce wild-type levels of skin lesions in mouse model of skin infection, indicating that Sda1 but not other DNases (namely Spd and Spd3) is the major DNase that contributes to virulence of MGAS5005 in mouse models (Sumbly et al., 2005a). Furthermore, the virulence of Sda1 was extensively characterized by Buchanan et al. using M1T1 strain 5448

(Buchanan et al., 2006). They found that Sda1 promotes GAS neutrophil resistance and virulence through degrading neutrophil extracellular traps (NETs), which is a significant innate immune structure composed of chromatin and granule proteins (Brinkmann et al., 2004; Buchanan et al., 2006). A recent study further suggested that Sda1 could also cleave bacterial DNA to prevent TLR9-mediated recognition of GAS by host innate immune cells, which damped the secretion of inflammatory cytokines, resulting in GAS survival in a murine model of necrotizing fasciitis (Uchiyama et al., 2012).

DNase as a bacterial virulence factor is not limited to GAS alone. Sda1 homologues can be found in various virulent pathogens, such as *Plasmodium falciparum*, *Staphylococcus aureus* and *Streptococcus pneumoniae* (Aziz et al., 2004a; Beiter et al., 2006; Thammavongsa et al., 2013). These DNases share the similar function in degrading NETs, suggesting their potential as a therapeutic target. Inhibition of DNase activity or development of therapeutic antibodies neutralizing the activity of these enzymes may facilitate the resolution of pathogenic infections. As an example, mice immunized with recombinant *Plasmodium* DNase exhibit increased immunity against lethal challenge of *P. falciparum* (Chang et al., 2016).

### 1.2 The superantigen SpeA2 – a potent scarlet fever toxin

GAS produces numerous pyrogenic toxins called superantigens. Unlike the normal antigens that are presented within the major histocompatibility complex class II (MHC II) of antigen-presenting cells and the T cell receptor (TCR), superantigens are capable to crosslink MHC II and TCR outside the peptide-binding groove, causing non-specific activation of T cells and an immense cytokine release (Fraser and Proft, 2008; Li et al., 1999). Therefore, superantigens have been implicated as the major culprit of acute infections such as sepsis, necrotizing fasciitis, and toxic shock syndrome (Norrby-Teglund et al., 2001; Proft et al., 2003; Salgado-Pabon et al., 2013; Sriskandan et al., 1996). As a representative of superantigens, SpeA has been known as a scarlet fever toxin, preferentially stimulating human T cells bearing specific TCR  $\beta$ -chain variable

domains (Abe et al., 1991; Braun et al., 1993; Leonard et al., 1991). Accordingly, SpeA has been shown enhancing acute nasopharyngeal infection by GAS in mice expressing human MHC II, while vaccination with inactive SpeA or SpeA devoid of MHC II binding protected mice from GAS infection (Kasper et al., 2014; Zeppa et al., 2017).

GAS encodes four SpeA variants, namely SpeA1 through SpeA4. SpeA2 differs from SpeA1 by a single amino acid substitution at position 80 from glycine to serine, which is close to the zinc-binding site in SpeA for recognition of the MHC II molecules (Earhart et al., 2000; Kline and Collins, 1996, 1997; Nelson et al., 1991; Papageorgiou et al., 1999). Importantly, all contemporary M1 isolates exclusively harbor the SpeA2 allele (Musser et al., 1991; Musser et al., 1993). In fact, a more recent research performed by Nasser et al., after analysis of genome sequences from 3,615 M1 strains, indicate that SpeA2 variant subsequently evolved from the old SpeA1 variant via a single-nucleotide change leading to glycine-to-serine substitution (Nasser et al., 2014). Although only one single amino acid difference from SpeA1, recombinant SpeA2 has a higher binding affinity for the MHC II molecules (Abe et al., 1991; Kline and Collins, 1996, 1997; Papageorgiou et al., 1999). This increased binding affinity may lead to more severe effects in the host, and could explain why SpeA2 has been detected in a majority of M1T1 GAS strains isolated from patients with streptococcal toxic shock syndrome (Musser et al., 1991; Musser et al., 1993).

SpeA2 expression is controlled by multiple factors, either from GAS or from host. Kazmi et al. initially failed to induce SpeA expression in invasive M1T1 isolates at varying culture conditions, whereas detected SpeA2 production from mouse-passaged isolates (Kazmi et al., 2001). The expression of SpeA2 was shown to correlate reciprocally and temporally to the downregulation of SpeB, and it was regulated negatively by the global regulator, the control of virulence two-component system CovRS (also known as CsrRS) in M1T1 (Kazmi et al., 2001; Sumbly et al., 2006). Interestingly, SpeA2 expression can be induced in cocultures with human peripheral blood mononuclear cells *ex vivo* (Kansal et al., 2005). The

host signals, such as transferrin and lactoferrin, play a role in regulation of SpeA2 expression, and may be implicated in GAS invasive infections (Kansal et al., 2005).

## 2. The second event: replacement through recombination of streptolysin O and NAD<sup>+</sup>-glycohydrolase

The second genetic recombination event occurring is that M1T1 clone acquires a 36-kb chromosomal region, which encodes streptolysin O (SLO) and NAD<sup>+</sup>-glycohydrolase (NADase, also called *Streptococcus pyogenes* NAD-glycohydrolase, SPN). SLO is an oxygen-labile streptococcal hemolytic exotoxin that belongs to a large family of cholesterol-dependent cytolysins (Tweten, 2005), while NADase is an enzyme that cleaves  $\beta$ -NAD<sup>+</sup> to produce ADP-ribose and nicotinamide (Ghosh et al., 2010; Grushoff et al., 1975). SLO and NADase, known as well-characterized secreted toxins of GAS, have been widely found in isolates from patients with toxic shock syndrome and other severe infections. For instance, Muller-Alouf et al. reported all 212 isolates from patients with severe invasive GAS infections secreted SLO (Muller-Alouf et al., 1997). Furthermore, a strong association has been proposed between isolates causing severe invasive GAS infections and the production of NADase, and all M1 strains isolated after 1988 were positive for NADase (Stevens et al., 2000; Tatsuno et al., 2007). Compared to bacteriophage-encoded Sda1 and SpeA2, which are exclusively found in the epidemic M1T1 clones, SLO and NADase are chromosome-encoded and present in many invasive M types of GAS such as M1, M3 and M12 (Ikebe et al., 2010; Muller-Alouf et al., 1997). However, by analyzing single-nucleotide polymorphism of contemporary GAS isolates, Sumby et al. identified a considerable difference between genomes of pre-epidemic M1 strain SF370 and M1T1 isolate MGAS5005 (Sumby et al., 2005b). The latter contains a ~36 kb chromosomal region encoding SLO and NADase, which was suggested to be acquired from a M12 GAS strain by horizontal gene transfer and recombinational replacement (Sumby et al., 2005b). It is believed that acquisition of this 36-kb region together with the integration of bacteriophage-encoded Sda1 and SpeA2, cooperatively leads to the emergence and rapid global spread of the



contemporary epidemic M1T1 clone (Nasser et al., 2014; Wilkening and Federle, 2017; Zhu et al., 2015).

### 2.1 SLO – the potent pore-forming toxin

Nearly all GAS clinical isolates possess a highly conserved *slo* gene encoding SLO, which is detectable during exponential and early stationary growth phases of GAS isolates in the culture medium (Alouf, 1980). Moreover, SLO expression is highly upregulated in epidemic M1T1 GAS strains (Sumbly et al., 2006; Zhu et al., 2015). It is also suggested that the expression of *slo* gene is upregulated by cathelicidin antimicrobial peptide LL-37, preventing GAS to be killed by human cells (Love et al., 2012).

As a potent pore-forming toxin, SLO has been shown to lyse numerous host cells through destructing cytoplasmic membrane integrity. SLO causes lysis in eukaryotic cells by binding to membrane cholesterol in a monomeric form, followed by oligomerization and pore formation, a mechanism similarly to that mediated by staphylococcal  $\alpha$ -toxin and lytic membrane attack complex of complement (Bhakdi et al., 1985; Duncan and Schlegel, 1975; Hugo et al., 1986; Niedermeyer, 1985; Otto, 2014; Tegla et al., 2011). Cells, such as erythrocytes, neutrophils, macrophages, platelets, and keratinocytes, are the reported targets of SLO (Duncan and Schlegel, 1975; Launay and Alouf, 1979; Sierig et al., 2003). Similar with streptolysin S, SLO contributes to  $\beta$ -hemolytic activity of GAS on the blood agar (Fontaine et al., 2003; Sierig et al., 2003). However, its hemolytic activity is inactivated by oxygen, while streptolysin S is oxygen-stable.

SLO contributes to GAS virulence with multiple functions. It has been demonstrated that *slo*-deficient GAS mutants decreased their virulence in various murine models of invasive diseases (Ato et al., 2008; Fontaine et al., 2003; Limbago et al., 2000; Timmer et al., 2009). More in details, studies suggested that SLO contributes to GAS virulence in the early stage of infections when GAS encounters epithelial barrier and phagocytes including neutrophils and macrophages (Ato et al., 2008; Fontaine et al., 2003; Limbago et al., 2000;

Timmer et al., 2009). In term of neutrophils, sublytic SLO sufficiently suppresses neutrophil oxidative burst, which could be reversed by free cholesterol and anti-SLO antibodies (Uchiyama et al., 2015). Furthermore, SLO impairs neutrophil degranulation, interleukin-8 secretion and antibacterial activity (Uchiyama et al., 2015). Interestingly, SLO at sublytic concentrations also inhibits neutrophil chemotaxis, possibly due to that SLO induces a rapid and massive shedding of L-selectin, the cell adhesion molecule guiding leukocytes to sites of inflammation (Walcheck et al., 1996; Walev et al., 2000; Van Epps and Andersen, 1974). However, in epidemic M1T1 clones, SLO functionally induces neutrophil lysis and cell death (Timmer et al., 2009). It could be explained by the observation that epidemic M1T1 clones typically produce a high level of SLO (Sumbly et al., 2006). During neutrophil lysis, SLO apparently activates neutrophils through a p38 MAPK signaling pathway, resulting in the release of heparin-binding protein, LL-37, defensins, and elastase (Andersen and Duncan, 1980; Nilsson et al., 2006). Moreover, SLO induces the coaggregation of neutrophils and platelets in rat model, which is largely mediated by platelet P-selectin and may contributes to the vascular dysfunction and ischemic destruction observed in patients with toxic shock syndrome (Bryant et al., 2005).

Macrophages, as similar with neutrophils, response to the stimulation of recombinant SLO through activation of the NLRP3 inflammasome, leading to IL-1 $\beta$  secretion and pyroptosis (Keyel et al., 2013; Mitsui et al., 2002). Notably, GAS also requires SLO to activate intracellular NLRP3 inflammasome in macrophages in a caspase-1 dependent manner, independently of TLR signaling that is critical for macrophages exposed to certain bacterial pore-forming toxins (Harder et al., 2009; Mariathasan et al., 2006). This finding was constitutively mimicked by Timmer et al. who showed an accelerated, caspase-dependent SLO-induced macrophage apoptosis contributed to M1T1 GAS immune evasion and virulence (Timmer et al., 2009). Interestingly, not only caspase-1, caspases-3 and -7 are also involved in SLO-induced macrophage apoptosis, indicating that SLO rather activates multiple inflammatory programmed cell death pathways (Goldmann et al., 2009; Timmer et al., 2009). In addition to the lytic activity and modulation of

inflammation, SLO prevents internalization of GAS into lysosomes (Hakansson et al., 2005; Logsdon et al., 2011). SLO-deficient GAS was internalized directly via a clathrin-dependent pathway and rapidly transported into lysosomes, and killed through the lysosomal degradation (Hakansson et al., 2005; Logsdon et al., 2011). In contrast, SLO prevented lysosomal colocalization with intracellular GAS and acidification of GAS-containing vacuoles, and conferred GAS resist internalization and intracellular killing by pharyngeal epithelial cells (Hakansson et al., 2005; Logsdon et al., 2011). Collectively, these suggest a lysis-independent function of SLO, which is being a translocator delivering GAS toxins, in particular NADase into cell cytoplasm (Magassa et al., 2010).

## 2.2 NADase – an intracellular enzyme and toxin

GAS NADase or SPN is a secreted enzyme that catalyzes the hydrolysis of the nicotinamide-ribose bond of NAD<sup>+</sup> to yield nicotinamide and ADP-ribose (Ghosh et al., 2010; Grushoff et al., 1975). Because cyclic ADP-ribose is a potent second messenger for intracellular calcium homeostasis (Guse, 2004; Lee, 2001), it has been suggested that NADase could be translocated into the cytosol of host cells to deplete cellular NAD pools and disrupting cellular metabolism, leading to host cell injury and death (Bricker et al., 2005; Bricker et al., 2002; Madden et al., 2001; Michos et al., 2006).

NADase is directly toxic for a wide variety of host cells, and toxic to *E. coli* and yeast when they were employed for expression of recombinant GAS NADase (Ghosh et al., 2010; Tatsuno et al., 2007). However, NADase has no toxic effects on GAS, suggesting an alternative factor from GAS that essentially regulates the toxicity of NADase within GAS. This factor, designated as immunity factor for SPN (IFS) by Meehl et al., is an endogenous inhibitor of NADase activity (Kimoto et al., 2006; Meehl et al., 2005). IFS is co-expressed as a small protein of 161 amino acids with NADase and forms a stable complex with the later at a 1:1 molar ratio in the cytoplasm of GAS. Binding of IFS to NADase in a form of complex blocks its access to the substrate  $\beta$ -NAD<sup>+</sup>, therefore competitively inhibiting activities of NADase and protecting GAS from exhaustion of NAD<sup>+</sup> (Kimoto et al., 2006; Meehl

et al., 2005; Smith et al., 2011). Furthermore, recombinant NADase can be normally produced in *E. coli* when co-expressed with the inhibitor IFS, and dissociated from IFS by treatment with sodium thiocyanate (Kimoto et al., 2006; Meehl et al., 2005). However, to be active and toxic to host cells, NADase need to be released from the stable complex with IFS during secretion by GAS, for which the mechanism remains to be elucidated.

NADase acts specifically as an intracellular toxin to the host. The cytotoxic effects of NADase on host requires SLO that delivers NADase to the cytoplasm of human cells, making it difficult to distinguish toxic effects of NADase from those of SLO (Karasawa et al., 1995; Magassa et al., 2010; Sharma et al., 2016). Alternatively, Sharma et al. fused active NADase to anthrax toxin, which mediates delivery of NADase into human oropharyngeal keratinocytes, independently of SLO (Sharma et al., 2016). This active NADase, but not the inactive form of NADase, induced cell death of keratinocytes. Moreover, NADase/SLO-deficient GAS had a defective intracellular survival in human keratinocytes, however, this defective survival could be rescued by delivery of anthrax toxin-fused NADase into keratinocytes (Sharma et al., 2016). These indicate that NADase acts specifically as an intracellular toxin, mediating cytotoxicity and promoting intracellular survival of GAS in host cells (Bricker et al., 2002; Sharma et al., 2016). Furthermore, the toxic effects of NADase in the host are also demonstrated *in vivo* using mouse models of invasive infections, which showed a significantly attenuation of virulence in GAS lacking NADase activity (Bricker et al., 2005; Zhu et al., 2017). NADase also has an immune regulatory function through inhibiting inflammasome-dependent IL-1 $\beta$  release from infected macrophages, independent on SLO-mediated translocation of NADase into the host cell cytosol (Hancz et al., 2017).

### 2.3 SLO and NADase – One plus one equals more than two

As two potent toxins of GAS, SLO and NADase play relevant roles in GAS pathogenesis. More importantly, both toxins act synergistically and closely associate with each other. For example, the genes encoding SLO and NADase

are co-transcribed, while two proteins can be co-purified from the culture supernatants of GAS (Shany et al., 1973). SLO mediates the translocation of NADase into human epithelial cells, while NADase binds to SLO and enhances its activity (Michos et al., 2006; Velarde et al., 2017). Interaction between SLO and NADase seems to be a win-win event that stabilizes both toxins and increases their activities (Michos et al., 2006; Velarde et al., 2017). Furthermore, GAS with both SLO and NADase induces an augmented cell injury of human keratinocytes (Michos et al., 2006; Velarde et al., 2017). Interestingly, SLO stimulates xenophagy in pharyngeal keratinocytes. However, SLO and NADase coordinately prevent maturation of GAS-containing autophagosomes, thereby prolonging GAS intracellular survival (O'Seaghda and Wessels, 2013). Similarly, both toxins also mediate GAS intracellular survival and cytotoxicity for macrophages. They do not inhibit maturation of GAS-containing lysophagosomes, but rather prevent phagolysosome acidification in macrophages that may serve as reservoirs or vehicles to enable persistent GAS infection in the host (Bastiat-Sempe et al., 2014).

The synergistical effects of SLO and NADase have been elucidated not only in host cells *ex vivo* but also in various mouse models of invasive GAS infections. Bricker et al. showed that mutants deficient in SLO and NADase activity were significantly attenuated for virulence compared with the wild-type parent M3 GAS strain in mouse models of invasive soft-tissue infection and septicemia (Bricker et al., 2005). In an epidemic M1T1 GAS background, SLO and NADase had equally capacities to cause necrotizing myositis (Zhu et al., 2017). Moreover, mutants lacking SLO and NADase are impaired to resist killing by human neutrophils, and are significantly attenuated in the bacteremia and soft tissue infection models (Zhu et al., 2017). Therefore, recombinational replacement of SLO and NADase-encoded genetic region from M12 GAS contributes significantly to the emergence of contemporary epidemic M1T1 isolates.

## II. Selection of hypervirulent M1T1 GAS clone in the host

Phenotypic switching refers to a switch between two phenotypic states with

different gene expression patterns, which leads to variation in morphology, physiology, and pathogenicity of bacterial pathogens. For example, pathogen *S. aureus* switches from normal colony phenotype to a slow-growing, small colony variant phenotype that facilitates bacterial persistent in host cells and recurrent infections (Proctor et al., 2006). GAS, particularly the invasive M1T1 and M3 types, also undergoes a switch from a SpeB-positive and SpeA negative (SpeB<sup>+</sup>/SpeA<sup>-</sup>) phenotype to a SpeB<sup>-</sup>/SpeA<sup>+</sup> phenotype when they are recovered from infected human or passaged in mouse, which is termed as *in vivo* selection (Ikebe et al., 2010; Kazmi et al., 2001; Walker et al., 2007). The *in vivo* selection, characterized as the loss of SpeB activity, has been associated with the mutations in global regulatory proteins of GAS (Carroll and Musser, 2011). GAS possesses various global regulators including two-component regulatory systems and stand-alone regulators (Kreikemeyer et al., 2003). Of these global regulators, CovRS has been well characterized (Graham et al., 2002; Sumbly et al., 2006). CovRS represents a sophisticated regulatory network negatively controlling expression of multiple virulence factors including SpeB (Graham et al., 2002). However, CovRS is highly prone to spontaneous mutation in the host, which results in downregulation of SpeB production but enhancement of virulence, leading to the emergence of variants with hypervirulent/invasive capacities (Graham et al., 2002; Ikebe et al., 2010; Trevino et al., 2009).

### 1. CovRS – the control of GAS virulence

CovRS consists of a membrane-bound histidine kinase CovS and a cognate response regulator CovR. As a typical sensor histidine kinase, CovS contains a surface-exposed extracellular domain, two membrane-spanning domains, a cytosolic HAMP domain (present in Histidine kinases, Adenyl cyclases, Methyl-accepting proteins and Phosphatases), and a histidine kinase-like ATPase (HATPase) domain (Tran-Winkler et al., 2011). The extracellular domain acts to sense various environmental stimuli or stresses, e.g., Mg<sup>2+</sup> concentration, external pH and temperature, iron starvation and LL-37 (Dalton and Scott, 2004; Froehlich et al., 2009; Gryllos et al., 2007; Gryllos et al., 2003; Gryllos et al., 2008). It is presumed that the environmental signals could influence the histidine

autophosphorylation of HATPase domain in CovS and subsequent phosphotransfer to the aspartate residue of CovR, which determines CovR phosphorylation status (Dalton and Scott, 2004; Tran-Winkler et al., 2011). CovR acts primarily as a repressor of gene expression whose phosphorylation enhances its binding to regulated promoters (Dalton and Scott, 2004; Federle and Scott, 2002; Gusa et al., 2006; Gusa and Scott, 2005; Horstmann et al., 2015; Horstmann et al., 2014; Tran-Winkler et al., 2011), mediating the cellular responses through altering distinct transcriptional profiling of GAS (Churchward, 2007; Dalton et al., 2006; Graham et al., 2002; Gryllos et al., 2007; Gryllos et al., 2003; Gusa et al., 2006; Horstmann et al., 2015; Horstmann et al., 2014; Tran-Winkler et al., 2011; Trevino et al., 2009).

In response to specific environmental stimuli, CovRS mediates distinct signal transduction and strikingly different transcriptomes. Human cationic LL-37, being a well-characterized stimulus of GAS CovRS, exhibits a broad spectrum of antimicrobial activity as well as immunomodulatory activity (Durr et al., 2006). M1T1 GAS clone is more resistant to the antimicrobial activity of human LL-37 through several mechanisms, for example, sequestering and neutralizing its activity by M1 protein, and inactivating LL-37 by the streptococcal inhibitor of complement and secreted streptococcal proteins (Durr et al., 2006; Frick et al., 2003; Johansson et al., 2008; LaRock et al., 2015; Nyberg et al., 2004). Notably, LL-37 binds directly to the extracellular domain of CovS, which dephosphorylates CovR and subsequently release the CovR-mediated repression of expression of multiple virulence factors including Sda1, SpeA2, SLO, NADase and the hyaluronic acid capsule (Gryllos et al., 2008; Love et al., 2012; Tran-Winkler et al., 2011; Velarde et al., 2014). The LL-37 signaling through CovRS leads to a marked increase of GAS virulence by promoting GAS resistance to the killing by human oropharyngeal keratinocytes, neutrophils, and macrophages (Gryllos et al., 2008; Love et al., 2012; Tran-Winkler et al., 2011). Interestingly, LL-37 signaling-upregulated GAS virulence can be adversely damped by elevated extracellular  $Mg^{2+}$ , although it may not be physiologically relevant (Gryllos et al., 2007; Gryllos et al., 2003; Gryllos et al., 2008; Tran-Winkler et al., 2011). The

opposite effects on expression of CovRS-regulated genes through LL-37 and Mg<sup>2+</sup> signaling, as an example, suggest the complexity of CovRS regulatory system, especially when invasive GAS survives in host.

## 2. The spontaneous mutation of CovRS in the host

In concert with CovRS-controlled enhanced GAS virulence elicited by host LL-37, CovRS undergoes spontaneous mutations more frequently in patients with severe GAS infections, leading to the emergence of hypervirulent/invasive variants. This naturally occurring CovRS mutation has been reported in various M types of GAS including not only M1 but also M3, M12, M28, M49 and M89 GAS clinical isolates (Ikebe et al., 2010; Uchiyama et al., 2012). However, CovRS mutations occur with a higher frequency in the invasive M1T1 isolates, which contributes to the phenotype of SpeB/SpeA<sup>+</sup> (Aziz et al., 2004b; Engleberg et al., 2001; Ikebe et al., 2010; Kansal et al., 2010). The mutations in most cases, either in CovR or CovS, in the form of nucleotide deletions, point mutations, or insertions, eventually cause dysfunction of CovRS, leading to enhanced virulence in mouse models of invasive disease (Ikebe et al., 2010; Li et al., 2014; Mayfield et al., 2014). CovRS mutation variants, for example, either generated in the laboratory or recovered after passage *in vivo*, produce elevated levels of CovRS-targeted virulent factors, especially that are involved in GAS dissemination into deep tissue and organs in the cases of necrotizing fasciitis and toxic shock syndrome (Engleberg et al., 2001; Graham et al., 2002; Horstmann et al., 2011; Kansal et al., 2010; Mayfield et al., 2014; Miyoshi-Akiyama et al., 2006; Sumbly et al., 2006; Tatsuno et al., 2013; Trevino et al., 2009).

It is worth noting that CovRS mutations not only mediate the upregulation of virulence, but also modulate the cellular responses of GAS, *e.g.*, nutrient metabolism, protein biosynthesis, and environmental adaptation. More fundamentally, CovRS mutation changes the transcriptome profile of M1T1 GAS clone from a phenotype favoring epithelial colonization to the one that promotes immune evasion and dissemination of GAS (Graham et al., 2002; Hollands et al., 2010; Sumbly et al., 2006). It suggests, potentially, that CovRS mutations may



shape GAS virulence in combination with other transcriptional regulators that regulate carbon source utilization and nitrogen metabolism during GAS infection (Shelburne et al., 2010). Furthermore, CovRS mutations facilitate virulence through dismissing the production of SpeB, which proteolytically degrades multiple virulence factors (Aziz et al., 2004b; Walker et al., 2007).

### 3. The selection pressure for CovRS mutation variants

What pressure or factors in the host drive the occurrence of mutations in CovRS has not been well understood. However, several studies have provided clues that help us understand the *in vivo* selection of CovRS mutations. Two types of selection pressure have been suggested to govern the mutation of CovRS in the host, one from host, another from the bacteria itself.

The selective force from the host is navigated to the innate immunity where neutrophils play a dominant role (Li et al., 2014). Neutrophils are the most abundant innate immune cells, killing invading pathogens through a comprehensive mechanism consisting of phagocytosis, respiratory burst and antimicrobial molecules-mediated killing, and NETs formation (Dohrmann et al., 2016). Compared to other bacteria, GAS is more successful to counteract the antimicrobial activities of neutrophils, which could be attributed to the observation that neutrophils provide selection pressure for the phenotypic switch of M1T1 GAS via the mutation of CovRS in the mouse infection models (Kobayashi et al., 2003; Li et al., 2014). Accordingly, such a selection was inhibited in mice whose neutrophils were depleted by specific monoclonal antibodies or when neutrophil migration was impaired during infection due to the deficiency in chemokine receptor 2 (Li et al., 2014). The recovered CovRS mutation variants from mice showed a hypervirulent phenotype as similarly as found in the clinical isolates from patients with toxic shock syndrome and other severe infections (Ikebe et al., 2010; Li et al., 2014).


GAS virulence factors also act as selective pressures that determine the CovRS mutation in the host. At least two virulence factors, M1 protein and hyaluronic acid

capsule, have been proposed being involved (Cole et al., 2010). M protein, as the major virulence factor of GAS, mediates GAS colonization of host epithelium, promotes GAS resistance to phagocytosis, inactivates LL-37 activity, as well as facilitates bacterial survival in neutrophils and NETs (Carlsson et al., 2003; Horstmann et al., 1988; Horstmann et al., 1992; LaRock et al., 2015; Lauth et al., 2009; Oehmcke et al., 2010; Staali et al., 2006). Similarly, hyaluronic acid capsule increases GAS resistance to phagocytosis and survival within NETs (Cole et al., 2010; Dale et al., 1996; Wessels et al., 1991). Both M1 protein and hyaluronic acid capsule share a common capacity that is to resist neutrophil-mediated killing (Buchanan et al., 2006; Lauth et al., 2009; Staali et al., 2003; Wessels et al., 1991). Consequently, GAS deficient in M1 protein or hyaluronic acid capsule failed to undergo phenotypic switching and was rapidly cleared by the host immune responses (Cole et al., 2010; Liu et al., 2015). Therefore, the occurrence of CovRS mutations in the host is rather a strategy for GAS to counteract host immunity, particularly the antimicrobial activities of neutrophils.

Sda1 has been also regarded as a selective force for the emergence of hypervirulent isolates in M1T1 GAS 5448 (Walker et al., 2007). Similarly as M1 protein and hyaluronic acid capsule, Sda1 confers GAS virulence through degrading NETs and increasing GAS survival in the host (Brinkmann et al., 2004; Buchanan et al., 2006; Uchiyama et al., 2012). However, horizontal transfer of the Sda1-encoding bacteriophage into the genome of M1 SF370 didn't confer GAS switch to hypervirulent *covRS* mutants in the mouse model as the phage donor strain 5448 did (Venturini et al., 2013). Moreover, we found that M1 protein, instead of Sda1, contributed to the CovRS mutation of two typical M1T1 GAS isolates in the host (Liu et al., 2015).

In a word, the selection of CovRS mutations in the host, theoretically, fits the paradigm of "Stress-Response" (Figure 1). To survive in host detrimental circumstance ("Stress"), GAS must adapt itself to evade immune attack ("Response"). It seems that GAS virulence factors including M1 protein and the capsule but not Sda1, provide primary and synergistical protection when the

M1T1 clone colonizes and invades host niches, where it survives and has opportunities to adjust the transcriptional profile through mutating in the global regulatory proteins (Cole et al., 2010; Feng et al., 2016; Liu et al., 2015; Venturini et al., 2013). Furthermore, when the detrimental circumstance or the selection pressure do not exist, GAS tends to attenuate virulence at the expense of downregulation of M protein (Zhou et al., 2013).



**Figure 1.** Schematic paradigm of “Stress-Response” driving the emergence of hypervirulent M1T1 GAS clone. Host innate immunity consisting of immune cells, complement and antibodies provides a “Stress” environment for GAS. To survive such a detrimental circumstance, GAS must adapt itself in response to immune stress. By acquiring genetic regions encoding Sda1, SpeA2, SLO and NADase and mutating its global regulatory proteins such as CovRS, GAS changes the transcriptional profile that promotes its hypervirulence, leading to the successful emergence of pandemic M1T1 clone.

### Concluding Remarks

The emergence of highly successful and globally disseminated M1T1 GAS clone has been identified as a threat to human health. This review highlights the importance of genetic recombination events, through which M1T1 GAS obtains virulence factors including Sda1, SpeA2, SLO and NADase. Further, this review highlights the significance of selection pressures from either neutrophils or bacteria, that modulate the upregulation of GAS virulence via the mutation of CovRS. Finally, genetic recombination alongside with the selective force

cooperatively drive the emergence of successful pandemic M1T1 isolates. By understanding the evolutionary pressures that select and shape the hypervirulent M1T1 clone, we could potentially develop new therapeutic strategies to tackle challenges when dealing with the globally disseminated M1T1 GAS clone.

### Acknowledgment

The author would like to thank Ms. Kinga Balogh Sivars (AstraZeneca AB R&D, Sweden) for expert proofreading.

### Disclosures

The author is currently employed by AstraZeneca AB R&D, Sweden. AstraZeneca has no financial conflict of interest.

### References

- Abe, J., Forrester, J., Nakahara, T., Lafferty, J.A., Kotzin, B.L., and Leung, D.Y. (1991). Selective stimulation of human T cells with streptococcal erythrogenic toxins A and B. *J Immunol* *146*, 3747-3750.
- Alouf, J.E. (1980). Streptococcal toxins (streptolysin O, streptolysin S, erythrogenic toxin). *Pharmacol Ther* *11*, 661-717.
- Andersen, B.R., and Duncan, J.L. (1980). Activation of human neutrophil metabolism by streptolysin O. *J Infect Dis* *141*, 680-685.
- Ato, M., Ikebe, T., Kawabata, H., Takemori, T., and Watanabe, H. (2008). Incompetence of neutrophils to invasive group A *streptococcus* is attributed to induction of plural virulence factors by dysfunction of a regulator. *PLoS One* *3*, e3455.
- Aziz, R.K., Edwards, R.A., Taylor, W.W., Low, D.E., McGeer, A., and Kotb, M. (2005). Mosaic prophages with horizontally acquired genes account for the emergence and diversification of the globally disseminated M1T1 clone of *Streptococcus pyogenes*. *J Bacteriol* *187*, 3311-3318.

- Aziz, R.K., Ismail, S.A., Park, H.W., and Kotb, M. (2004a). Post-proteomic identification of a novel phage-encoded streptodornase, Sda1, in invasive M1T1 *Streptococcus pyogenes*. *Mol Microbiol* *54*, 184-197.
- Aziz, R.K., and Kotb, M. (2008). Rise and persistence of global M1T1 clone of *Streptococcus pyogenes*. *Emerg Infect Dis* *14*, 1511-1517.
- Aziz, R.K., Pabst, M.J., Jeng, A., Kansal, R., Low, D.E., Nizet, V., and Kotb, M. (2004b). Invasive M1T1 group A *Streptococcus* undergoes a phase-shift *in vivo* to prevent proteolytic degradation of multiple virulence factors by SpeB. *Mol Microbiol* *51*, 123-134.
- Banks, D.J., Porcella, S.F., Barbian, K.D., Beres, S.B., Phillips, L.E., Voyich, J.M., DeLeo, F.R., Martin, J.M., Somerville, G.A., and Musser, J.M. (2004). Progress toward characterization of the group A *Streptococcus* metagenome: complete genome sequence of a macrolide-resistant serotype M6 strain. *J Infect Dis* *190*, 727-738.
- Bastiat-Sempe, B., Love, J.F., Lomayeva, N., and Wessels, M.R. (2014). Streptolysin O and NAD-glycohydrolase prevent phagolysosome acidification and promote group A *Streptococcus* survival in macrophages. *MBio* *5*, e01690-01614.
- Beiter, K., Wartha, F., Albiger, B., Normark, S., Zychlinsky, A., and Henriques-Normark, B. (2006). An endonuclease allows *Streptococcus pneumoniae* to escape from neutrophil extracellular traps. *Curr Biol* *16*, 401-407.
- Beres, S.B., Sylva, G.L., Barbian, K.D., Lei, B., Hoff, J.S., Mammarella, N.D., Liu, M.Y., Smoot, J.C., Porcella, S.F., Parkins, L.D., *et al.* (2002). Genome sequence of a serotype M3 strain of group A *Streptococcus*: phage-encoded toxins, the high-virulence phenotype, and clone emergence. *Proc Natl Acad Sci U S A* *99*, 10078-10083.
- Bhakdi, S., Trantum-Jensen, J., and Sziegoleit, A. (1985). Mechanism of membrane damage by streptolysin-O. *Infect Immun* *47*, 52-60.
- Braun, M.A., Gerlach, D., Hartwig, U.F., Ozegowski, J.H., Romagne, F., Carrel, S., Kohler, W., and Fleischer, B. (1993). Stimulation of human T cells by streptococcal "superantigen" erythrogenic toxins (scarlet fever toxins). *J Immunol* *150*, 2457-2466.

- Bricker, A.L., Carey, V.J., and Wessels, M.R. (2005). Role of NADase in virulence in experimental invasive group A streptococcal infection. *Infect Immun* 73, 6562-6566.
- Bricker, A.L., Cywes, C., Ashbaugh, C.D., and Wessels, M.R. (2002). NAD<sup>+</sup>-glycohydrolase acts as an intracellular toxin to enhance the extracellular survival of group A streptococci. *Mol Microbiol* 44, 257-269.
- Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D.S., Weinrauch, Y., and Zychlinsky, A. (2004). Neutrophil extracellular traps kill bacteria. *Science* 303, 1532-1535.
- Bryant, A.E., Bayer, C.R., Chen, R.Y., Guth, P.H., Wallace, R.J., and Stevens, D.L. (2005). Vascular dysfunction and ischemic destruction of tissue in *Streptococcus pyogenes* infection: the role of streptolysin O-induced platelet/neutrophil complexes. *J Infect Dis* 192, 1014-1022.
- Buchanan, J.T., Simpson, A.J., Aziz, R.K., Liu, G.Y., Kristian, S.A., Kotb, M., Feramisco, J., and Nizet, V. (2006). DNase expression allows the pathogen group A *Streptococcus* to escape killing in neutrophil extracellular traps. *Curr Biol* 16, 396-400.
- Carapetis, J.R., Steer, A.C., Mulholland, E.K., and Weber, M. (2005). The global burden of group A streptococcal diseases. *Lancet Infect Dis* 5, 685-694.
- Carlsson, F., Berggard, K., Stalhammar-Carlemalm, M., and Lindahl, G. (2003). Evasion of phagocytosis through cooperation between two ligand-binding regions in *Streptococcus pyogenes* M protein. *J Exp Med* 198, 1057-1068.
- Carroll, R.K., and Musser, J.M. (2011). From transcription to activation: how group A streptococcus, the flesh-eating pathogen, regulates SpeB cysteine protease production. *Mol Microbiol* 81, 588-601.
- Chang, Z., Jiang, N., Zhang, Y., Lu, H., Yin, J., Wahlgren, M., Cheng, X., Cao, Y., and Chen, Q. (2016). The TatD-like DNase of Plasmodium is a virulence factor and a potential malaria vaccine candidate. *Nat Commun* 7, 11537.
- Churchward, G. (2007). The two faces of Janus: virulence gene regulation by CovR/S in group A streptococci. *Mol Microbiol* 64, 34-41.
- Cleary, P.P., LaPenta, D., Vessela, R., Lam, H., and Cue, D. (1998). A globally disseminated M1 subclone of group A streptococci differs from other subclones

by 70 kilobases of prophage DNA and capacity for high-frequency intracellular invasion. *Infect Immun* 66, 5592-5597.

Cole, J.N., Barnett, T.C., Nizet, V., and Walker, M.J. (2011). Molecular insight into invasive group A streptococcal disease. *Nat Rev Microbiol* 9, 724-736.

Cole, J.N., Pence, M.A., von Kockritz-Blickwede, M., Hollands, A., Gallo, R.L., Walker, M.J., and Nizet, V. (2010). M protein and hyaluronic acid capsule are essential for *in vivo* selection of covRS mutations characteristic of invasive serotype M1T1 group A *Streptococcus*. *MBio* 1 (4):e00191-10.

Dale, J.B., Washburn, R.G., Marques, M.B., and Wessels, M.R. (1996). Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. *Infect Immun* 64, 1495-1501.

Dalton, T.L., Collins, J.T., Barnett, T.C., and Scott, J.R. (2006). RscA, a member of the MDR1 family of transporters, is repressed by CovR and required for growth of *Streptococcus pyogenes* under heat stress. *J Bacteriol* 188, 77-85.

Dalton, T.L., and Scott, J.R. (2004). CovS inactivates CovR and is required for growth under conditions of general stress in *Streptococcus pyogenes*. *J Bacteriol* 186, 3928-3937.

Dohrmann, S., Cole, J.N., and Nizet, V. (2016). Conquering Neutrophils. *PLoS Pathog* 12, e1005682.

Duncan, J.L., and Schlegel, R. (1975). Effect of streptolysin O on erythrocyte membranes, liposomes, and lipid dispersions. A protein-cholesterol interaction. *J Cell Biol* 67, 160-174.

Durr, U.H., Sudheendra, U.S., and Ramamoorthy, A. (2006). LL-37, the only human member of the cathelicidin family of antimicrobial peptides. *Biochim Biophys Acta* 1758, 1408-1425.

Earhart, C.A., Vath, G.M., Roggiani, M., Schlievert, P.M., and Ohlendorf, D.H. (2000). Structure of streptococcal pyrogenic exotoxin A reveals a novel metal cluster. *Protein Sci* 9, 1847-1851.

Engleberg, N.C., Heath, A., Miller, A., Rivera, C., and DiRita, V.J. (2001). Spontaneous mutations in the CsrRS two-component regulatory system of *Streptococcus pyogenes* result in enhanced virulence in a murine model of skin and soft tissue infection. *J Infect Dis* 183, 1043-1054.

- Federle, M.J., and Scott, J.R. (2002). Identification of binding sites for the group A streptococcal global regulator CovR. *Mol Microbiol* 43, 1161-1172.
- Feng, W., Liu, M., Chen, D.G., Yiu, R., Fang, F.C., and Lei, B. (2016). Contemporary Pharyngeal and Invasive emm1 and Invasive emm12 Group A *Streptococcus* Isolates Exhibit Similar In Vivo Selection for CovRS Mutants in Mice. *PLoS One* 11, e0162742.
- Ferretti, J.J., McShan, W.M., Ajdic, D., Savic, D.J., Savic, G., Lyon, K., Primeaux, C., Sezate, S., Suvorov, A.N., Kenton, S., *et al.* (2001). Complete genome sequence of an M1 strain of *Streptococcus pyogenes*. *Proc Natl Acad Sci U S A* 98, 4658-4663.
- Fontaine, M.C., Lee, J.J., and Kehoe, M.A. (2003). Combined contributions of streptolysin O and streptolysin S to virulence of serotype M5 *Streptococcus pyogenes* strain Manfredo. *Infect Immun* 71, 3857-3865.
- Fraser, J.D., and Proft, T. (2008). The bacterial superantigen and superantigen-like proteins. *Immunol Rev* 225, 226-243.
- Frick, I.M., Akesson, P., Rasmussen, M., Schmidtchen, A., and Bjorck, L. (2003). SIC, a secreted protein of *Streptococcus pyogenes* that inactivates antibacterial peptides. *J Biol Chem* 278, 16561-16566.
- Froehlich, B.J., Bates, C., and Scott, J.R. (2009). *Streptococcus pyogenes* CovRS mediates growth in iron starvation and in the presence of the human cationic antimicrobial peptide LL-37. *J Bacteriol* 191, 673-677.
- Ghosh, J., Anderson, P.J., Chandrasekaran, S., and Caparon, M.G. (2010). Characterization of *Streptococcus pyogenes* beta-NAD<sup>+</sup> glycohydrolase: re-evaluation of enzymatic properties associated with pathogenesis. *J Biol Chem* 285, 5683-5694.
- Goldmann, O., Sastalla, I., Wos-Oxley, M., Rohde, M., and Medina, E. (2009). *Streptococcus pyogenes* induces oncosis in macrophages through the activation of an inflammatory programmed cell death pathway. *Cell Microbiol* 11, 138-155.
- Graham, M.R., Smoot, L.M., Migliaccio, C.A., Virtaneva, K., Sturdevant, D.E., Porcella, S.F., Federle, M.J., Adams, G.J., Scott, J.R., and Musser, J.M. (2002). Virulence control in group A *Streptococcus* by a two-component gene regulatory



system: global expression profiling and in vivo infection modeling. *Proc Natl Acad Sci U S A* **99**, 13855-13860.

Grushoff, P.S., Shany, S., and Bernheimer, A.W. (1975). Purification and properties of streptococcal nicotinamide adenine dinucleotide glycohydrolase. *J Bacteriol* **122**, 599-605.

Gryllos, I., Grifantini, R., Colaprico, A., Jiang, S., Deforce, E., Hakansson, A., Telford, J.L., Grandi, G., and Wessels, M.R. (2007). Mg(2+) signalling defines the group A streptococcal CsrRS (CovRS) regulon. *Mol Microbiol* **65**, 671-683.

Gryllos, I., Levin, J.C., and Wessels, M.R. (2003). The CsrR/CsrS two-component system of group A *Streptococcus* responds to environmental Mg<sup>2+</sup>. *Proc Natl Acad Sci U S A* **100**, 4227-4232.

Gryllos, I., Tran-Winkler, H.J., Cheng, M.F., Chung, H., Bolcome, R., 3rd, Lu, W., Lehrer, R.I., and Wessels, M.R. (2008). Induction of group A *Streptococcus* virulence by a human antimicrobial peptide. *Proc Natl Acad Sci U S A* **105**, 16755-16760.

Gusa, A.A., Gao, J., Stringer, V., Churchward, G., and Scott, J.R. (2006). Phosphorylation of the group A Streptococcal CovR response regulator causes dimerization and promoter-specific recruitment by RNA polymerase. *J Bacteriol* **188**, 4620-4626.

Gusa, A.A., and Scott, J.R. (2005). The CovR response regulator of group A streptococcus (GAS) acts directly to repress its own promoter. *Mol Microbiol* **56**, 1195-1207.

Guse, A.H. (2004). Regulation of calcium signaling by the second messenger cyclic adenosine diphosphoribose (cADPR). *Curr Mol Med* **4**, 239-248.

Hakansson, A., Bentley, C.C., Shakhnovic, E.A., and Wessels, M.R. (2005). Cytolysin-dependent evasion of lysosomal killing. *Proc Natl Acad Sci U S A* **102**, 5192-5197.

Hancz, D., Westerlund, E., Bastiat-Sempe, B., Sharma, O., Valfridsson, C., Meyer, L., Love, J.F., O'Seaghdha, M., Wessels, M.R., and Persson, J.J. (2017). Inhibition of Inflammasome-Dependent Interleukin 1beta Production by Streptococcal NAD(+)-Glycohydrolase: Evidence for Extracellular Activity. *MBio* **8** (4): e00756-17.

Harder, J., Franchi, L., Munoz-Planillo, R., Park, J.H., Reimer, T., and Nunez, G. (2009). Activation of the Nlrp3 inflammasome by *Streptococcus pyogenes* requires streptolysin O and NF-kappa B activation but proceeds independently of TLR signaling and P2X7 receptor. *J Immunol* 183, 5823-5829.

Hollands, A., Pence, M.A., Timmer, A.M., Osvath, S.R., Turnbull, L., Whitchurch, C.B., Walker, M.J., and Nizet, V. (2010). Genetic switch to hypervirulence reduces colonization phenotypes of the globally disseminated group A streptococcus M1T1 clone. *J Infect Dis* 202, 11-19.

Horstmann, N., Sahasrabhojane, P., Saldana, M., Ajami, N.J., Flores, A.R., Sumbly, P., Liu, C.G., Yao, H., Su, X., Thompson, E., *et al.* (2015). Characterization of the effect of the histidine kinase CovS on response regulator phosphorylation in group A *Streptococcus*. *Infect Immun* 83, 1068-1077.

Horstmann, N., Sahasrabhojane, P., Suber, B., Kumaraswami, M., Olsen, R.J., Flores, A., Musser, J.M., Brennan, R.G., and Shelburne, S.A., 3rd (2011). Distinct single amino acid replacements in the control of virulence regulator protein differentially impact streptococcal pathogenesis. *PLoS Pathog* 7, e1002311.

Horstmann, N., Saldana, M., Sahasrabhojane, P., Yao, H., Su, X., Thompson, E., Koller, A., and Shelburne, S.A., 3rd (2014). Dual-site phosphorylation of the control of virulence regulator impacts group a streptococcal global gene expression and pathogenesis. *PLoS Pathog* 10, e1004088.

Horstmann, R.D., Sievertsen, H.J., Knobloch, J., and Fischetti, V.A. (1988). Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. *Proc Natl Acad Sci U S A* 85, 1657-1661.

Horstmann, R.D., Sievertsen, H.J., Leippe, M., and Fischetti, V.A. (1992). Role of fibrinogen in complement inhibition by streptococcal M protein. *Infect Immun* 60, 5036-5041.

Hugo, F., Reichwein, J., Arvand, M., Kramer, S., and Bhakdi, S. (1986). Use of a monoclonal antibody to determine the mode of transmembrane pore formation by streptolysin O. *Infect Immun* 54, 641-645.

Ikebe, T., Ato, M., Matsumura, T., Hasegawa, H., Sata, T., Kobayashi, K., and Watanabe, H. (2010). Highly frequent mutations in negative regulators of multiple

virulence genes in group A streptococcal toxic shock syndrome isolates. *PLoS Pathog* 6, e1000832.

Johansson, L., Thulin, P., Sendi, P., Herten, E., Linder, A., Akesson, P., Low, D.E., Agerberth, B., and Norrby-Teglund, A. (2008). Cathelicidin LL-37 in severe *Streptococcus pyogenes* soft tissue infections in humans. *Infect Immun* 76, 3399-3404.

Kansal, R.G., Aziz, R.K., and Kotb, M. (2005). Modulation of expression of superantigens by human transferrin and lactoferrin: a novel mechanism in host-*Streptococcus* interactions. *J Infect Dis* 191, 2121-2129.

Kansal, R.G., Datta, V., Aziz, R.K., Abdeltawab, N.F., Rowe, S., and Kotb, M. (2010). Dissection of the molecular basis for hypervirulence of an in vivo-selected phenotype of the widely disseminated M1T1 strain of group A *Streptococcus* bacteria. *J Infect Dis* 201, 855-865.

Karasawa, T., Takasawa, S., Yamakawa, K., Yonekura, H., Okamoto, H., and Nakamura, S. (1995). NAD(+)-glycohydrolase from *Streptococcus pyogenes* shows cyclic ADP-ribose forming activity. *FEMS Microbiol Lett* 130, 201-204.

Kasper, K.J., Zeppa, J.J., Wakabayashi, A.T., Xu, S.X., Mazzuca, D.M., Welch, I., Baroja, M.L., Kotb, M., Cairns, E., Cleary, P.P., *et al.* (2014). Bacterial superantigens promote acute nasopharyngeal infection by *Streptococcus pyogenes* in a human MHC Class II-dependent manner. *PLoS Pathog* 10, e1004155.

Kazmi, S.U., Kansal, R., Aziz, R.K., Hooshdaran, M., Norrby-Teglund, A., Low, D.E., Halim, A.B., and Kotb, M. (2001). Reciprocal, temporal expression of SpeA and SpeB by invasive M1T1 group a streptococcal isolates in vivo. *Infect Immun* 69, 4988-4995.

Keyel, P.A., Roth, R., Yokoyama, W.M., Heuser, J.E., and Salter, R.D. (2013). Reduction of streptolysin O (SLO) pore-forming activity enhances inflammasome activation. *Toxins (Basel)* 5, 1105-1118.

Kimoto, H., Fujii, Y., Hirano, S., Yokota, Y., and Taketo, A. (2006). Genetic and biochemical properties of streptococcal NAD-glycohydrolase inhibitor. *J Biol Chem* 281, 9181-9189.

Kline, J.A., and Runge, J.W. (1994). Streptococcal pharyngitis: a review of pathophysiology, diagnosis, and management. *J Emerg Med* 12, 665-680.

Kline, J.B., and Collins, C.M. (1996). Analysis of the superantigenic activity of mutant and allelic forms of streptococcal pyrogenic exotoxin A. *Infect Immun* 64, 861-869.

Kline, J.B., and Collins, C.M. (1997). Analysis of the interaction between the bacterial superantigen streptococcal pyrogenic exotoxin A (SpeA) and the human T-cell receptor. *Mol Microbiol* 24, 191-202.

Kobayashi, S.D., Braughton, K.R., Whitney, A.R., Voyich, J.M., Schwan, T.G., Musser, J.M., and DeLeo, F.R. (2003). Bacterial pathogens modulate an apoptosis differentiation program in human neutrophils. *Proc Natl Acad Sci U S A* 100, 10948-10953.

Kreikemeyer, B., McIver, K.S., and Podbielski, A. (2003). Virulence factor regulation and regulatory networks in *Streptococcus pyogenes* and their impact on pathogen-host interactions. *Trends Microbiol* 11, 224-232.

Lancefield, R.C. (1933). A Serological Differentiation of Human and Other Groups of Hemolytic Streptococci. *J Exp Med* 57, 571-595.

Lancefield, R.C. (1962). Current knowledge of type-specific M antigens of group A streptococci. *J Immunol* 89, 307-313.

Lappin, E., and Ferguson, A.J. (2009). Gram-positive toxic shock syndromes. *Lancet Infect Dis* 9, 281-290.

LaRock, C.N., Dohrmann, S., Todd, J., Corriden, R., Olson, J., Johannssen, T., Lepenies, B., Gallo, R.L., Ghosh, P., and Nizet, V. (2015). Group A Streptococcal M1 Protein Sequesters Cathelicidin to Evade Innate Immune Killing. *Cell Host Microbe* 18, 471-477.

Launay, J.M., and Alouf, J.E. (1979). Biochemical and ultrastructural study of the disruption of blood platelets by streptolysin O. *Biochim Biophys Acta* 556, 278-291.

Lauth, X., von Kockritz-Blickwede, M., McNamara, C.W., Myskowski, S., Zinkernagel, A.S., Beall, B., Ghosh, P., Gallo, R.L., and Nizet, V. (2009). M1 protein allows Group A streptococcal survival in phagocyte extracellular traps through cathelicidin inhibition. *J Innate Immun* 1, 202-214.

- Lee, H.C. (2001). Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. *Annu Rev Pharmacol Toxicol* 41, 317-345.
- Leonard, B.A., Lee, P.K., Jenkins, M.K., and Schlievert, P.M. (1991). Cell and receptor requirements for streptococcal pyrogenic exotoxin T-cell mitogenicity. *Infect Immun* 59, 1210-1214.
- Li, H., Llera, A., Malchiodi, E.L., and Mariuzza, R.A. (1999). The structural basis of T cell activation by superantigens. *Annu Rev Immunol* 17, 435-466.
- Li, J., Liu, G., Feng, W., Zhou, Y., Liu, M., Wiley, J.A., and Lei, B. (2014). Neutrophils select hypervirulent CovRS mutants of M1T1 group A *Streptococcus* during subcutaneous infection of mice. *Infect Immun* 82, 1579-1590.
- Limbago, B., Penumalli, V., Weinrick, B., and Scott, J.R. (2000). Role of streptolysin O in a mouse model of invasive group A streptococcal disease. *Infect Immun* 68, 6384-6390.
- Liu, G., Feng, W., Li, D., Liu, M., Nelson, D.C., and Lei, B. (2015). The Mga Regulon but Not Deoxyribonuclease Sda1 of Invasive M1T1 Group A *Streptococcus* Contributes to In Vivo Selection of CovRS Mutations and Resistance to Innate Immune Killing Mechanisms. *Infect Immun* 83, 4293-4303.
- Logsdon, L.K., Hakansson, A.P., Cortes, G., and Wessels, M.R. (2011). Streptolysin O inhibits clathrin-dependent internalization of group A *Streptococcus*. *MBio* 2, e00332-00310.
- Love, J.F., Tran-Winkler, H.J., and Wessels, M.R. (2012). Vitamin D and the human antimicrobial peptide LL-37 enhance group a streptococcus resistance to killing by human cells. *MBio* 3(5): e00394-12.
- Maamary, P.G., Ben Zakour, N.L., Cole, J.N., Hollands, A., Aziz, R.K., Barnett, T.C., Cork, A.J., Henningham, A., Sanderson-Smith, M., McArthur, J.D., *et al.* (2012). Tracing the evolutionary history of the pandemic group A streptococcal M1T1 clone. *FASEB J* 26, 4675-4684.
- Madden, J.C., Ruiz, N., and Caparon, M. (2001). Cytolysin-mediated translocation (CMT): a functional equivalent of type III secretion in gram-positive bacteria. *Cell* 104, 143-152.

Magassa, N., Chandrasekaran, S., and Caparon, M.G. (2010). *Streptococcus pyogenes* cytolysin-mediated translocation does not require pore formation by streptolysin O. *EMBO Rep* 11, 400-405.

Mariathasan, S., Weiss, D.S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W.P., Weinrauch, Y., Monack, D.M., and Dixit, V.M. (2006). Cryopyrin activates the inflammasome in response to toxins and ATP. *Nature* 440, 228-232.

Mayfield, J.A., Liang, Z., Agrahari, G., Lee, S.W., Donahue, D.L., Ploplis, V.A., and Castellino, F.J. (2014). Mutations in the control of virulence sensor gene from *Streptococcus pyogenes* after infection in mice lead to clonal bacterial variants with altered gene regulatory activity and virulence. *PLoS One* 9, e100698.

Meehl, M.A., Pinkner, J.S., Anderson, P.J., Hultgren, S.J., and Caparon, M.G. (2005). A novel endogenous inhibitor of the secreted streptococcal NAD-glycohydrolase. *PLoS Pathog* 1, e35.

Michos, A., Gryllos, I., Hakansson, A., Srivastava, A., Kokkotou, E., and Wessels, M.R. (2006). Enhancement of streptolysin O activity and intrinsic cytotoxic effects of the group A streptococcal toxin, NAD-glycohydrolase. *J Biol Chem* 281, 8216-8223.

Mitsui, K., Takano, K., Nakatani, S., Nambu, H., Shibata, F., and Nakagawa, H. (2002). Chemokine production by rat macrophages stimulated with streptolysin O from *Streptococcus pyogenes*. *Microbiol Immunol* 46, 37-45.

Miyoshi-Akiyama, T., Ikebe, T., Watanabe, H., Uchiyama, T., Kirikae, T., and Kawamura, Y. (2006). Use of DNA arrays to identify a mutation in the negative regulator, *csrR*, responsible for the high virulence of a naturally occurring type M3 group A streptococcus clinical isolate. *J Infect Dis* 193, 1677-1684.

Moon, A.F., Krahn, J.M., Lu, X., Cuneo, M.J., and Pedersen, L.C. (2016). Structural characterization of the virulence factor Sda1 nuclease from *Streptococcus pyogenes*. *Nucleic Acids Res* 44, 3946-3957.

Muller-Alouf, H., Geoffroy, C., Geslin, P., Bouvet, A., Felten, A., Gunther, E., Ozegowski, J.H., and Alouf, J.E. (1997). Streptococcal pyrogenic exotoxin A, streptolysin O, exoenzymes, serotype and biotype profiles of *Streptococcus*

*pyogenes* isolates from patients with toxic shock syndrome and other severe infections. Zentralbl Bakteriol 286, 421-433.

Musser, J.M., Hauser, A.R., Kim, M.H., Schlievert, P.M., Nelson, K., and Selander, R.K. (1991). *Streptococcus pyogenes* causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci U S A 88, 2668-2672.

Musser, J.M., Kapur, V., Kanjilal, S., Shah, U., Musher, D.M., Barg, N.L., Johnston, K.H., Schlievert, P.M., Henrichsen, J., Gerlach, D., *et al.* (1993). Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of *Streptococcus pyogenes* expressing allelic variants of pyrogenic exotoxin A (Scarlet fever toxin). J Infect Dis 167, 337-346.

Nasser, W., Beres, S.B., Olsen, R.J., Dean, M.A., Rice, K.A., Long, S.W., Kristinsson, K.G., Gottfredsson, M., Vuopio, J., Raisanen, K., *et al.* (2014). Evolutionary pathway to increased virulence and epidemic group A *Streptococcus* disease derived from 3,615 genome sequences. Proc Natl Acad Sci U S A 111, E1768-1776.

Nelson, D.C., Garbe, J., and Collin, M. (2011). Cysteine proteinase SpeB from *Streptococcus pyogenes* - a potent modifier of immunologically important host and bacterial proteins. Biol Chem 392, 1077-1088.

Nelson, K., Schlievert, P.M., Selander, R.K., and Musser, J.M. (1991). Characterization and clonal distribution of four alleles of the speA gene encoding pyrogenic exotoxin A (scarlet fever toxin) in *Streptococcus pyogenes*. J Exp Med 174, 1271-1274.

Niedermeyer, W. (1985). Interaction of streptolysin-O with biomembranes: kinetic and morphological studies on erythrocyte membranes. Toxicon 23, 425-439.

Nilsson, M., Sorensen, O.E., Morgelin, M., Weineisen, M., Sjobring, U., and Herwald, H. (2006). Activation of human polymorphonuclear neutrophils by streptolysin O from *Streptococcus pyogenes* leads to the release of proinflammatory mediators. Thromb Haemost 95, 982-990.

Norrby-Teglund, A., Thulin, P., Gan, B.S., Kotb, M., McGeer, A., Andersson, J., and Low, D.E. (2001). Evidence for superantigen involvement in severe group a streptococcal tissue infections. J Infect Dis 184, 853-860.

- Nyberg, P., Rasmussen, M., and Bjorck, L. (2004). alpha2-Macroglobulin-proteinase complexes protect *Streptococcus pyogenes* from killing by the antimicrobial peptide LL-37. *J Biol Chem* 279, 52820-52823.
- O'Seaghda, M., and Wessels, M.R. (2013). Streptolysin O and its co-toxin NAD-glycohydrolase protect group A *Streptococcus* from Xenophagic killing. *PLoS Pathog* 9, e1003394.
- Oehmcke, S., Shannon, O., Morgelin, M., and Herwald, H. (2010). Streptococcal M proteins and their role as virulence determinants. *Clin Chim Acta* 411, 1172-1180.
- Olsen, R.J., and Musser, J.M. (2010). Molecular pathogenesis of necrotizing fasciitis. *Annu Rev Pathol* 5, 1-31.
- Otto, M. (2014). *Staphylococcus aureus* toxins. *Curr Opin Microbiol* 17, 32-37.
- Papageorgiou, A.C., Collins, C.M., Gutman, D.M., Kline, J.B., O'Brien, S.M., Tranter, H.S., and Acharya, K.R. (1999). Structural basis for the recognition of superantigen streptococcal pyrogenic exotoxin A (SpeA1) by MHC class II molecules and T-cell receptors. *EMBO J* 18, 9-21.
- Proctor, R.A., von Eiff, C., Kahl, B.C., Becker, K., McNamara, P., Herrmann, M., and Peters, G. (2006). Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. *Nat Rev Microbiol* 4, 295-305.
- Proft, T., Sriskandan, S., Yang, L., and Fraser, J.D. (2003). Superantigens and streptococcal toxic shock syndrome. *Emerg Infect Dis* 9, 1211-1218.
- Ralph, A.P., and Carapetis, J.R. (2013). Group a streptococcal diseases and their global burden. *Curr Top Microbiol Immunol* 368, 1-27.
- Salgado-Pabon, W., Breshears, L., Spaulding, A.R., Merriman, J.A., Stach, C.S., Horswill, A.R., Peterson, M.L., and Schlievert, P.M. (2013). Superantigens are critical for *Staphylococcus aureus* Infective endocarditis, sepsis, and acute kidney injury. *MBio* 4.
- Shaikh, N., Leonard, E., and Martin, J.M. (2010). Prevalence of streptococcal pharyngitis and streptococcal carriage in children: a meta-analysis. *Pediatrics* 126, e557-564.



Shany, S., Grushoff, P.S., and Bernheimer, A.W. (1973). Physical separation of streptococcal nicotinamide adenine dinucleotide glycohydrolase from streptolysin O. *Infect Immun* 7, 731-734.

Sharma, O., O'Seaghdha, M., Velarde, J.J., and Wessels, M.R. (2016). NAD<sup>+</sup>-Glycohydrolase Promotes Intracellular Survival of Group A *Streptococcus*. *PLoS Pathog* 12, e1005468.

Shelburne, S.A., Olsen, R.J., Suber, B., Sahasrabhojane, P., Sumby, P., Brennan, R.G., and Musser, J.M. (2010). A combination of independent transcriptional regulators shapes bacterial virulence gene expression during infection. *PLoS Pathog* 6, e1000817.

Sierig, G., Cywes, C., Wessels, M.R., and Ashbaugh, C.D. (2003). Cytotoxic effects of streptolysin o and streptolysin s enhance the virulence of poorly encapsulated group a streptococci. *Infect Immun* 71, 446-455.

Smeesters, P.R., McMillan, D.J., and Sriprakash, K.S. (2010). The streptococcal M protein: a highly versatile molecule. *Trends Microbiol* 18, 275-282.

Smith, C.L., Ghosh, J., Elam, J.S., Pinkner, J.S., Hultgren, S.J., Caparon, M.G., and Ellenberger, T. (2011). Structural basis of *Streptococcus pyogenes* immunity to its NAD<sup>+</sup> glycohydrolase toxin. *Structure* 19, 192-202.

Sriskandan, S., Moyes, D., and Cohen, J. (1996). Detection of circulating bacterial superantigen and lymphotoxin-alpha in patients with streptococcal toxic-shock syndrome. *Lancet* 348, 1315-1316.

Staali, L., Bauer, S., Morgelin, M., Bjorck, L., and Tapper, H. (2006). *Streptococcus pyogenes* bacteria modulate membrane traffic in human neutrophils and selectively inhibit azurophilic granule fusion with phagosomes. *Cell Microbiol* 8, 690-703.

Staali, L., Morgelin, M., Bjorck, L., and Tapper, H. (2003). *Streptococcus pyogenes* expressing M and M-like surface proteins are phagocytosed but survive inside human neutrophils. *Cell Microbiol* 5, 253-265.

Steer, A.C., Law, I., Matatolu, L., Beall, B.W., and Carapetis, J.R. (2009). Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. *Lancet Infect Dis* 9, 611-616.

Stevens, D.L., Salmi, D.B., McIndoo, E.R., and Bryant, A.E. (2000). Molecular epidemiology of nga and NAD glycohydrolase/ADP-ribosyltransferase activity among *Streptococcus pyogenes* causing streptococcal toxic shock syndrome. *J Infect Dis* 182, 1117-1128.

Sumby, P., Barbian, K.D., Gardner, D.J., Whitney, A.R., Welty, D.M., Long, R.D., Bailey, J.R., Parnell, M.J., Hoe, N.P., Adams, G.G., *et al.* (2005a). Extracellular deoxyribonuclease made by group A *Streptococcus* assists pathogenesis by enhancing evasion of the innate immune response. *Proc Natl Acad Sci U S A* 102, 1679-1684.

Sumby, P., Porcella, S.F., Madrigal, A.G., Barbian, K.D., Virtaneva, K., Ricklefs, S.M., Sturdevant, D.E., Graham, M.R., Vuopio-Varkila, J., Hoe, N.P., *et al.* (2005b). Evolutionary origin and emergence of a highly successful clone of serotype M1 group a *Streptococcus* involved multiple horizontal gene transfer events. *J Infect Dis* 192, 771-782.

Sumby, P., Whitney, A.R., Graviss, E.A., DeLeo, F.R., and Musser, J.M. (2006). Genome-wide analysis of group a streptococci reveals a mutation that modulates global phenotype and disease specificity. *PLoS Pathog* 2, e5.

Tatsuno, I., Okada, R., Zhang, Y., Isaka, M., and Hasegawa, T. (2013). Partial loss of CovS function in *Streptococcus pyogenes* causes severe invasive disease. *BMC Res Notes* 6, 126.

Tatsuno, I., Sawai, J., Okamoto, A., Matsumoto, M., Minami, M., Isaka, M., Ohta, M., and Hasegawa, T. (2007). Characterization of the NAD-glycohydrolase in streptococcal strains. *Microbiology* 153, 4253-4260.

Tegla, C.A., Cudrici, C., Patel, S., Trippe, R., 3rd, Rus, V., Niculescu, F., and Rus, H. (2011). Membrane attack by complement: the assembly and biology of terminal complement complexes. *Immunol Res* 51, 45-60.

Thammavongsa, V., Missiakas, D.M., and Schneewind, O. (2013). *Staphylococcus aureus* degrades neutrophil extracellular traps to promote immune cell death. *Science* 342, 863-866.

Timmer, A.M., Timmer, J.C., Pence, M.A., Hsu, L.C., Ghochani, M., Frey, T.G., Karin, M., Salvesen, G.S., and Nizet, V. (2009). Streptolysin O promotes group A

*Streptococcus* immune evasion by accelerated macrophage apoptosis. *J Biol Chem* 284, 862-871.

Tran-Winkler, H.J., Love, J.F., Gryllos, I., and Wessels, M.R. (2011). Signal transduction through CsrRS confers an invasive phenotype in group A *Streptococcus*. *PLoS Pathog* 7, e1002361.

Trevino, J., Perez, N., Ramirez-Pena, E., Liu, Z., Shelburne, S.A., 3rd, Musser, J.M., and Sumby, P. (2009). CovS simultaneously activates and inhibits the CovR-mediated repression of distinct subsets of group A *Streptococcus* virulence factor-encoding genes. *Infect Immun* 77, 3141-3149.

Tweten, R.K. (2005). Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. *Infect Immun* 73, 6199-6209.

Uchiyama, S., Andreoni, F., Schuepbach, R.A., Nizet, V., and Zinkernagel, A.S. (2012). DNase Sda1 allows invasive M1T1 Group A *Streptococcus* to prevent TLR9-dependent recognition. *PLoS Pathog* 8, e1002736.

Uchiyama, S., Dohrmann, S., Timmer, A.M., Dixit, N., Ghochani, M., Bhandari, T., Timmer, J.C., Sprague, K., Bubeck-Wardenburg, J., Simon, S.I., *et al.* (2015). Streptolysin O Rapidly Impairs Neutrophil Oxidative Burst and Antibacterial Responses to Group A *Streptococcus*. *Front Immunol* 6, 581.

Van Epps, D.E., and Andersen, B.R. (1974). Streptolysin O inhibition of neutrophil chemotaxis and mobility: nonimmune phenomenon with species specificity. *Infect Immun* 9, 27-33.

Velarde, J.J., Ashbaugh, M., and Wessels, M.R. (2014). The human antimicrobial peptide LL-37 binds directly to CsrS, a sensor histidine kinase of group A *Streptococcus*, to activate expression of virulence factors. *J Biol Chem* 289, 36315-36324.

Velarde, J.J., O'Seaghda, M., Baddal, B., Bastiat-Sempe, B., and Wessels, M.R. (2017). Binding of NAD(+)-Glycohydrolase to Streptolysin O Stabilizes Both Toxins and Promotes Virulence of Group A *Streptococcus*. *MBio* 8 (5): e01382-17.

Venturini, C., Ong, C.L., Gillen, C.M., Ben-Zakour, N.L., Maamary, P.G., Nizet, V., Beatson, S.A., and Walker, M.J. (2013). Acquisition of the Sda1-encoding

bacteriophage does not enhance virulence of the serotype M1 *Streptococcus pyogenes* strain SF370. *Infect Immun* 81, 2062-2069.

Walcheck, B., Kahn, J., Fisher, J.M., Wang, B.B., Fisk, R.S., Payan, D.G., Feehan, C., Betageri, R., Darlak, K., Spatola, A.F., *et al.* (1996). Neutrophil rolling altered by inhibition of L-selectin shedding in vitro. *Nature* 380, 720-723.

Walev, I., Tappe, D., Gulbins, E., and Bhakdi, S. (2000). Streptolysin O-permeabilized granulocytes shed L-selectin concomitantly with ceramide generation via neutral sphingomyelinase. *J Leukoc Biol* 68, 865-872.

Walker, M.J., Hollands, A., Sanderson-Smith, M.L., Cole, J.N., Kirk, J.K., Henningham, A., McArthur, J.D., Dinkla, K., Aziz, R.K., Kansal, R.G., *et al.* (2007). DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. *Nat Med* 13, 981-985.

Wang, C.H., Chiang-Ni, C., Kuo, H.T., Zheng, P.X., Tsou, C.C., Wang, S., Tsai, P.J., Chuang, W.J., Lin, Y.S., Liu, C.C., *et al.* (2013). Peroxide responsive regulator PerR of group A *Streptococcus* is required for the expression of phage-associated DNase Sda1 under oxidative stress. *PLoS One* 8, e81882.

Wessels, M.R., Moses, A.E., Goldberg, J.B., and DiCesare, T.J. (1991). Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. *Proc Natl Acad Sci U S A* 88, 8317-8321.

Wilkening, R.V., and Federle, M.J. (2017). Evolutionary Constraints Shaping *Streptococcus pyogenes*-Host Interactions. *Trends Microbiol* 25, 562-572.

Zeppa, J.J., Kasper, K.J., Mohorovic, I., Mazzuca, D.M., Haeryfar, S.M.M., and McCormick, J.K. (2017). Nasopharyngeal infection by *Streptococcus pyogenes* requires superantigen-responsive Vbeta-specific T cells. *Proc Natl Acad Sci U S A* 114 (38) 10226-10231.

Zhou, Y., Hanks, T.S., Feng, W., Li, J., Liu, G., Liu, M., and Lei, B. (2013). The *sagA/pel* locus does not regulate the expression of the M protein of the M1T1 lineage of group A *Streptococcus*. *Virulence* 4, 698-706.

Zhu, L., Olsen, R.J., Lee, J.D., Porter, A.R., DeLeo, F.R., and Musser, J.M. (2017). Contribution of Secreted NADase and Streptolysin O to the Pathogenesis of Epidemic Serotype M1 *Streptococcus pyogenes* Infections. *Am J Pathol* 187, 605-613.

Zhu, L., Olsen, R.J., Nasser, W., Beres, S.B., Vuopio, J., Kristinsson, K.G., Gottfredsson, M., Porter, A.R., DeLeo, F.R., and Musser, J.M. (2015). A molecular trigger for intercontinental epidemics of group A *Streptococcus*. *J Clin Invest* 125, 3545-3559.

